Investing in healthcare: CVS has lost 'competitive advantage'
In today's installment of Good Buy or Goodbye, host Julie Hyman welcomes on Washington Crossing Advisors senior portfolio manager Chad Morganlander to discuss the best investing strategies within the healthcare sector.
Morganlander names Elevance Health (ELV) as a stock to buy for investors, noting the fact the insurance provider's exposure to "US government pricing plans is much far less than their competitors." Morganlander also highlights the company's strong leadership team, noting they "are willing to walk away" from projects that are not "viable" for the business. Finally, he cites the attractive valuation, calling it "a steady eddie rising dividend stock you could put away for three to five years."
On the other hand, Morganlander advises investors to steer clear of CVS Health (CVS). The pharmacy chain took on "tremendous debt overhang" from acquiring Aetna in 2018. Furthermore, Morganlander believes CVS has lost its "competitive advantage" as the retail side of the business begins to slow down.
For more expert insight and the latest market action, click here to watch this full episode of Market Domination.
This post was written by Angel Smith